The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global HPV Vaccines Market Research Report 2024
Synopsis
Human papilloma virus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus. Available vaccines protect against either two, four, or nine types of HPV. All vaccines protect against at least HPV type 16 and 18 that cause the greatest risk of cervical cancer. It is estimated that they may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and possibly some mouth cancer. They additionally prevent some genital warts with the vaccines against 4 and 9 HPV types providing greater protection.
The global HPV Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for HPV Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HPV Vaccines.
Report Scope
The HPV Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HPV Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HPV Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
CSL
Emergent BioSolutions
GlaxoSmithKline
Johnson & Johnson
MedImmune
Merck
Pfizer
Sanofi Pasteur
Serum Institute
Segment by Type
Adolescents
Adults
Segment by Application
Male
Female
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of HPV Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of HPV Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Human papilloma virus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus. Available vaccines protect against either two, four, or nine types of HPV. All vaccines protect against at least HPV type 16 and 18 that cause the greatest risk of cervical cancer. It is estimated that they may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and possibly some mouth cancer. They additionally prevent some genital warts with the vaccines against 4 and 9 HPV types providing greater protection.
The global HPV Vaccines market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for HPV Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HPV Vaccines.
Report Scope
The HPV Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HPV Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HPV Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma
CSL
Emergent BioSolutions
GlaxoSmithKline
Johnson & Johnson
MedImmune
Merck
Pfizer
Sanofi Pasteur
Serum Institute
Segment by Type
Adolescents
Adults
Segment by Application
Male
Female
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of HPV Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of HPV Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 HPV Vaccines Market Overview
1.1 Product Overview and Scope of HPV Vaccines
1.2 HPV Vaccines Segment by Type
1.2.1 Global HPV Vaccines Market Value Comparison by Type (2024-2030)
1.2.2 Adolescents
1.2.3 Adults
1.3 HPV Vaccines Segment by Application
1.3.1 Global HPV Vaccines Market Value by Application: (2024-2030)
1.3.2 Male
1.3.3 Female
1.4 Global HPV Vaccines Market Size Estimates and Forecasts
1.4.1 Global HPV Vaccines Revenue 2019-2030
1.4.2 Global HPV Vaccines Sales 2019-2030
1.4.3 Global HPV Vaccines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 HPV Vaccines Market Competition by Manufacturers
2.1 Global HPV Vaccines Sales Market Share by Manufacturers (2019-2024)
2.2 Global HPV Vaccines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global HPV Vaccines Average Price by Manufacturers (2019-2024)
2.4 Global HPV Vaccines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of HPV Vaccines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of HPV Vaccines, Product Type & Application
2.7 HPV Vaccines Market Competitive Situation and Trends
2.7.1 HPV Vaccines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest HPV Vaccines Players Market Share by Revenue
2.7.3 Global HPV Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 HPV Vaccines Retrospective Market Scenario by Region
3.1 Global HPV Vaccines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global HPV Vaccines Global HPV Vaccines Sales by Region: 2019-2030
3.2.1 Global HPV Vaccines Sales by Region: 2019-2024
3.2.2 Global HPV Vaccines Sales by Region: 2025-2030
3.3 Global HPV Vaccines Global HPV Vaccines Revenue by Region: 2019-2030
3.3.1 Global HPV Vaccines Revenue by Region: 2019-2024
3.3.2 Global HPV Vaccines Revenue by Region: 2025-2030
3.4 North America HPV Vaccines Market Facts & Figures by Country
3.4.1 North America HPV Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America HPV Vaccines Sales by Country (2019-2030)
3.4.3 North America HPV Vaccines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe HPV Vaccines Market Facts & Figures by Country
3.5.1 Europe HPV Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe HPV Vaccines Sales by Country (2019-2030)
3.5.3 Europe HPV Vaccines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific HPV Vaccines Market Facts & Figures by Country
3.6.1 Asia Pacific HPV Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific HPV Vaccines Sales by Country (2019-2030)
3.6.3 Asia Pacific HPV Vaccines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America HPV Vaccines Market Facts & Figures by Country
3.7.1 Latin America HPV Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America HPV Vaccines Sales by Country (2019-2030)
3.7.3 Latin America HPV Vaccines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa HPV Vaccines Market Facts & Figures by Country
3.8.1 Middle East and Africa HPV Vaccines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa HPV Vaccines Sales by Country (2019-2030)
3.8.3 Middle East and Africa HPV Vaccines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global HPV Vaccines Sales by Type (2019-2030)
4.1.1 Global HPV Vaccines Sales by Type (2019-2024)
4.1.2 Global HPV Vaccines Sales by Type (2025-2030)
4.1.3 Global HPV Vaccines Sales Market Share by Type (2019-2030)
4.2 Global HPV Vaccines Revenue by Type (2019-2030)
4.2.1 Global HPV Vaccines Revenue by Type (2019-2024)
4.2.2 Global HPV Vaccines Revenue by Type (2025-2030)
4.2.3 Global HPV Vaccines Revenue Market Share by Type (2019-2030)
4.3 Global HPV Vaccines Price by Type (2019-2030)
5 Segment by Application
5.1 Global HPV Vaccines Sales by Application (2019-2030)
5.1.1 Global HPV Vaccines Sales by Application (2019-2024)
5.1.2 Global HPV Vaccines Sales by Application (2025-2030)
5.1.3 Global HPV Vaccines Sales Market Share by Application (2019-2030)
5.2 Global HPV Vaccines Revenue by Application (2019-2030)
5.2.1 Global HPV Vaccines Revenue by Application (2019-2024)
5.2.2 Global HPV Vaccines Revenue by Application (2025-2030)
5.2.3 Global HPV Vaccines Revenue Market Share by Application (2019-2030)
5.3 Global HPV Vaccines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Astellas Pharma
6.1.1 Astellas Pharma Corporation Information
6.1.2 Astellas Pharma Description and Business Overview
6.1.3 Astellas Pharma HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Astellas Pharma HPV Vaccines Product Portfolio
6.1.5 Astellas Pharma Recent Developments/Updates
6.2 CSL
6.2.1 CSL Corporation Information
6.2.2 CSL Description and Business Overview
6.2.3 CSL HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 CSL HPV Vaccines Product Portfolio
6.2.5 CSL Recent Developments/Updates
6.3 Emergent BioSolutions
6.3.1 Emergent BioSolutions Corporation Information
6.3.2 Emergent BioSolutions Description and Business Overview
6.3.3 Emergent BioSolutions HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Emergent BioSolutions HPV Vaccines Product Portfolio
6.3.5 Emergent BioSolutions Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Corporation Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline HPV Vaccines Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Corporation Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Johnson & Johnson HPV Vaccines Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 MedImmune
6.6.1 MedImmune Corporation Information
6.6.2 MedImmune Description and Business Overview
6.6.3 MedImmune HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 MedImmune HPV Vaccines Product Portfolio
6.6.5 MedImmune Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck HPV Vaccines Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Corporation Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Pfizer HPV Vaccines Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Sanofi Pasteur
6.9.1 Sanofi Pasteur Corporation Information
6.9.2 Sanofi Pasteur Description and Business Overview
6.9.3 Sanofi Pasteur HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Sanofi Pasteur HPV Vaccines Product Portfolio
6.9.5 Sanofi Pasteur Recent Developments/Updates
6.10 Serum Institute
6.10.1 Serum Institute Corporation Information
6.10.2 Serum Institute Description and Business Overview
6.10.3 Serum Institute HPV Vaccines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Serum Institute HPV Vaccines Product Portfolio
6.10.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 HPV Vaccines Industry Chain Analysis
7.2 HPV Vaccines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 HPV Vaccines Production Mode & Process
7.4 HPV Vaccines Sales and Marketing
7.4.1 HPV Vaccines Sales Channels
7.4.2 HPV Vaccines Distributors
7.5 HPV Vaccines Customers
8 HPV Vaccines Market Dynamics
8.1 HPV Vaccines Industry Trends
8.2 HPV Vaccines Market Drivers
8.3 HPV Vaccines Market Challenges
8.4 HPV Vaccines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
